Business Context and Reporting Period
This Form 8-K was filed by American BriVision (Holding) Corporation on July 24, 2017. The filing reports the entry into a Material Definitive Agreement with BioFirst Corporation, a Taiwan-based entity, to co-develop and commercialize a medical product.
Key Financial Metrics
The filing does not provide standard financial statements such as revenue, profit, cash flow, margins, or debt levels. The only specific financial figures disclosed relate to the new agreement:
- Total Payment Obligation: $3,000,000 to be paid in cash or stock by September 30, 2018.
- Upfront Payment: $300,000 (10% of total) paid upon signing.
- Payment Schedule: Two installments required.
- Revenue Sharing: Company entitled to 50% of future net licensing income or net sales profit.
- Cost Sharing: Development costs to be shared equally.
Material Changes
The primary material change is the execution of the Collaborative Agreement for the global license of "BFC-1401 Vitreous Substitute for Vitrectomy." This represents a strategic shift toward co-development and commercialization of a specific medical product, creating a new liability of $2.7 million remaining after the initial payment.
Guidance, Risks, and Related Parties
Related Party Transaction: Eugene Jiang, the Company's CEO, is also a director and common stock shareholder of BioFirst Corporation.
Risks and Contingencies: The filing includes forward-looking statements subject to risks including adverse regulatory decisions, safety information reviews, or clinical benefit findings inconsistent with recent publications. Management disclaims any obligation to update these statements except as required by law.
Outlook: The Company anticipates co-developing and commercializing the Product, though no specific revenue guidance or timeline for market entry is provided in this text.
Investor Verification Checklist
- Verify the Company's current liquidity to ensure it can meet the remaining $2.7 million payment obligation by September 30, 2018.
- Review the full text of the Collaborative Agreement (Exhibit 10.1) for specific terms regarding stock valuation if payment is made in equity.
- Assess the regulatory status and clinical trial data for BFC-1401 Vitreous Substitute.
- Confirm the extent of Eugene Jiang's financial interest in BioFirst to evaluate potential conflicts of interest.
- Check subsequent filings for updates on the development progress or any changes to the payment schedule.